OCC Innovation Park

Cancer Crosslinks 2017 will be streamed

/in , , , , /by

Cancer Crosslinks 2017 on January 26th features a really interesting program with presentations from international and Norwegian thought leaders within cancer research.

For those of you that may not be present at the conference in the Oslo Cancer Cluster Innovation Park, you may watch the presentations as we will live stream from 9:15 – 16:15.

Close to 250 participants from all over Norway have signed up for this years Cancer Crosslinks. The program for the 9. th Cancer Crosslinks is divided in three parts; recent findings regarding cancer & inflammation, personalised cancer medicine within hematological cancers and the emerging field of real-world evidence.

Cancer Crosslinks is hosted by Oslo Cancer Cluster and sponsored by BMS and AbbVie.

medlemshjul

Dehns is now member of the Oslo Cancer Cluster

/in , , , /by

Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster.

Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure.

As members, our aim is to advise and help protect the other members needs regarding innovations and intellectual property (IP) around cancer research, diagnosis and treatment.

With experts in this field, many of whom also have PhDs, we can help you build and manage your IP portfolio and strategy, including providing advice on the patentability of inventions, draft and file patent applications, represent you in opposition and other contentious proceedings, as well as advise on academia-industry collaborations and licensing agreements.

www.dehns.com

 

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

/in , , , /by

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

Oslo (Norway), 6 January 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities. The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster a Norwegian Centre of Expertise.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

Fantastic opening of the Oslo Cancer Cluster Innovation Park

/in , , /by

Oslo Cancer Cluster Innovation Park´s grand opening on August 24th became a very special day: More than 290 invited guests celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality.

 

In his speech, Jónas Einarsson told the intriguing history of cancer treatment and research in Norway since the early 1900s; driven by visionary men and funding from the people. A joint effort that has made cancer research one of the strongest areas within medicine and health research in Norway.

Einarsson also used the opportunity to thank some of the truly vital players in the realization of the Innovation Park: Tron Sanderud from Utstillingsplassen Eiendom, Toril Mølmen, former Head of Innovation Norways office in Oslo, Jan Vincents Johannesen, CEO Radium Foundation, Espen Susegg in SIVA and Pål Riis, former principal of Ullern High School.

 

OBOS will sponsor lab
The Opening Celebration started with the fantastic news from Arne Baumann, Chairman of the Board of the Innovation Park, that OBOS, apart from being one of the largest owners, also will sponsor the lab in the Oslo Cancer Cluster Incubator with 4MNOK.

Together with a 2 MNOK donation from the Radium Foundation the Incubator may offer state-of-the-art facilities to the companies and researchers renting here.

 

Erna tried out life as cancer researcher
Erna Solberg, Prime Minister of Norway surprised Mr. Einarsson with inviting him on stage cutting an orange bond to mark the official opening. In her speech, Solberg, said that health industry is an industry with double return in from of the values it creates for the society and patients in developing new treatments as well as developing jobs and value. She also said that the Innovation Park will play a major role in the development of the cancer treatment of the future.

After her speech, Einarsson guided the Prime Minister and the media on a short tour of the Innovation Park where Solberg ended up in the Incubator lab where she tried out the PCI-technology to kill cancer cells.

 

Erna_lab

Photo credit both pictures: Gunnar Kopperud.

Below we have gathered some of the media coverage, both nationally and abroad. We will also publish some videos from the opening later on. 

 

Media coverage:

TV:

Digital:

 

International coverage: